The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it

Xiaowei Xiong¹, Hong Liu¹, Lu Hua¹, Hui Zhao¹, Dongxue Wang² and Yishi Li*¹

Abstract

Background: Apolipoprotein CIII (apoCIII) is considered to impair the anti-atherogenic effect of high density lipoprotein (HDL) in coronary heart disease (CHD) patients, and apoCIII content in HDL (HDL-apoCIII) predicts CHD more accurately. However, the relationship between HDL-apoCIII and CHD, and the effect of statin treatment on HDL-apoCIII are still unclear. The aims of the study are to establish the association of HDL-apoCIII with CHD, and investigate the effect of statin treatment on HDL-apoCIII in CHD patients.

Methods: We conducted a hospital-based observational study. Totally 80 non-CHD patients and 120 CHD patients without statin treatment were previously enrolled in this study. All the CHD patients received statin treatment, and 63 of them were followed after 3 months of regular statin treatment. HDL sample of each patient was isolated by density gradient ultracentrifugation from fasting venous plasma, and HDL-apoCIII of each patient was measured by ELISA method.

Results: HDL-apoCIII was significantly higher in CHD patients than non-CHD patients (p < 0.05), and it was still an independent predictor of CHD after adjusting for other factors. Total plasma apoCIII, especially HDL-apoCIII was significantly elevated after statin treatment in CHD patients, whereas total cholesterol (TC), low density lipoprotein cholesterol (LDL-c) and apolipoprotein B (apoB) were decreased significantly (p < 0.05). Compared with CHD patients without diabetes mellitus (DM), the effect of statin treatment on apoCIII markers was minor in CHD patients with DM. And HDL-apoCIII correlated with plasma TG significantly in non-CHD and CHD patients (p < 0.05), but the correlation in CHD patients did not exist after statin treatment (p > 0.05).

Conclusions: HDL-apoCIII has a significant and positive association with CHD. Although conventional atherogenic lipid markers have a significantly decrease in CHD patients after statin treatment, HDL-apoCIII has a further elevation at the same time.

Keywords: Coronary heart disease (CHD), Apolipoprotein CIII (apoCIII), Statin, High density lipoprotein (HDL)

Introduction

Coronary heart disease (CHD) is a chronic inflammatory disease characterized with dyslipidemia [1–3]. Conventional lipid markers such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) are considered to associate with CHD positively or inversely [4, 5]. However, not all the CHD patients have dyslipidemia, and large clinical trials also fail to find more heart benefits by further elevating HDL-c [6, 7]. Increasing evidences suggest that apolipoproteins in lipoproteins or plasma may predict CHD better [5, 8], and the biological function of HDL is associated with its components much more [9].

As a major component of triglyceride-rich lipoproteins (TRL), apolipoprotein CIII (apoCIII) is considered to participate in the process of CHD by disturbing lipids lipolysis and promoting inflammation response [10–12]. Studies found that apoCIII or apoCIII-containing
lipoproteins had significant associations with CHD [8, 13, 14]. Even the antiatherogenic function of HDL was also impaired by apoCIII in CHD patients [15], and elevated apoCIII content in HDL (HDL-apoCIII) predicted the occurrence and progression of CHD in prospective or retrospective studies [16–18]. However, the relationship between HDL-apoCIII and CHD is still inconclusive because of the general usage of lipid-lowering drugs in almost all studies above. Lipid-lowering drugs, particularly statins, were demonstrated to reduce the progression of CHD and cardiovascular event significantly by decreasing atherogenic lipids [19, 20]. To date, it is still unclear if statin treatment has the same effect on HDL-apoCIII in CHD patients. The objectives of our study are to establish the association between HDL-apoCIII and CHD, and investigate the effect of statin treatment on HDL-apoCIII in CHD patients.

Method
Study design and population
The study was approved by the Ethics Committee of the Fuwai Hospital (Approval No. 2012–382) and was registered at http://clinicaltrials.gov/ (Identification Number: NCT 01543308). A written informed consent was provided to all study patients, and the study protocol conforms to the guidelines of Declaration of Helsinki. We conducted a hospital-based observational study. Patients without previously lipid-lowering treatment were consecutively recruited from April 2012 to March 2013 in Ward IV of Fuwai Hospital. Total 200 patients, including 80 non-CHD patients and 120 CHD patients, were entered into the study. CHD was diagnosed according to the angiographic results: stenosis ≥ 50 % in at least one major coronary artery. All 120 CHD patients received statin treatment (atorvastatin calcium 20 or 40 mg/day, rosuvastatin calcium 10 mg/day, pravastatin sodium 40 mg/day, or simvastatin 40 mg/day) regardless of whether a stent was implanted or not. Sixty-three CHD patients were followed after 3 months of regular statin treatment (detailed information about the statin treatment was listed in Additional files 3 and 4); 57 CHD patients refused to return for blood drawing. Considered the effect of Diabetes mellitus (DM) on lipids metabolism, the DM history of each patient was recorded. DM was diagnosed based on the National Cholesterol Education Program Adults Treatment Panel III or personal DM history. A total of 10 CHD patients with DM were followed in this study, including 5 patients used acarbose (2 of them also used glyburide or glipizide), 2 patients used insulin, and 3 patients used metformin, Chinese medicine and dietetic treatment respectively. The exclusion criteria included patients with any kinds of tumors and infections, severe liver or kidney diseases, uncontrolled hypertension, and severe heart failure.

Plasma preparation
Venous blood was collected from each patient after overnight fasting. Fresh plasma was obtained by centrifuging at 3000 r/min at 4 °C for 10 min immediately, and then aliquoting the plasma for lipids measurement or storage at −80 °C for HDL isolation and apoCIII measurement.

HDL isolation
As described previously [21], a HDL (d = 1.063-1.240 g/ml) sample of each patient was isolated from plasma by a sequential ultracentrifugation method. Briefly, plasma was adjusted to 1.240 g/ml by potassium bromide powder according to the Radding-Steining formula. The adjusted plasma samples were laid on the bottom of a centrifuge tube through KBr solution (d = 1.063 g/ml) and was centrifuged by 80 Ti Rotor ultracentrifuge (Beckman Coulter, USA) at the condition of 65000 r/min at 10 °C for 5 h. Finally the HDL sample was collected, desalted, freeze-dried, and resolved by deionized water for measurement.

Lipids measurement
Lipid markers including TC, TG, HDL-c, LDL-c, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB) and high sensitivity C-reactive protein (HsCRP) were measured by a biochemistry analyzer in the clinical laboratory centre of Fuwai hospital, as described previously [21]. And the plasma apoCIII concentrations and HDL-apoCIII were measured by using an ELISA kit (Abcam, UK). The concentrations of HDL samples were quantified by using BCA protein assay (Applygen Technologies Inc, China). The effect of the differences of HDL sample concentrations was considered, and all the ELISA results (ng/ml) of HDL-apoCIII were adjusted by the concentrations (ug/ml) of HDL samples, and the final HDL-apoCIII unit was reported in ug/mgHDL.

Statistical analysis
All the data were expressed as mean ± standard deviation (SD) or percent (%). Normality was checked before any analysis. The differences between groups were analyzed by student t-test, paired t-test or Mann–Whitney U test, or Wilcoxon rank test, as appropriate. A multivariate logistic regression model was used to analyze the odds ratios and 95 % confidence interval of lipid markers for predicting CHD. The correlations between lipid markers were analyzed by Pearson or Spearman correlation. The statistical analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, Illinois). A p-value of <0.05 was considered to be statistically significant.
Results
As shown Table 1, the elder males had a higher ratio of CHD \((p < 0.05)\), and the results consist to epidemiologic features. Data stratified by sex were listed in Additional file 1. Totally, compared with non-CHD patients, CHD patients had significantly higher apoB and HsCRP, and significantly lower HDL-c and apoAI than non-CHD patients \(( p < 0.05)\). There were no significant differences of TC, TG and LDL-c between CHD and non-CHD groups in this study \(( p > 0.05)\). However, there was no significant difference of total plasma apoCIII between two groups \(( p > 0.05)\), but HDL-apoCIII was significantly higher in CHD patients than non-CHD patients \(( p < 0.01)\).

In order to identify the relationship between HDL-apoCIII and CHD, we analyzed the associations between various lipid markers and CHD by multivariate logistic regression analysis (Table 2). HDL-apoCIII was still an independent predictor of CHD after adjusting for other factors \(( p < 0.05)\). Besides, sex, age, HDL-c, apoB and HsCRP were also significant predictors of CHD \(( p < 0.05)\). According to the data, HDL-c has a negative, and HDL-apoCIII has a positive association with CHD.

Sixty-three patients were followed in the study after 3 months of regular statin treatment, and the baseline characteristics of them were consistent with the CHD patients without follow-up data (Additional file 2, \( p > 0.05)\). The plasma apoCIII, especially HDL-apoCIII, had a significant elevation after statin treatment \(( p < 0.05)\), whereas HDL-c and ApoAI were elevated, and TC, LDL-c and apoB were decreased significantly (Table 3, \( p < 0.001)\). Although a similar effect on lipids changes was found in different statins, rosuvastatin showed a much stronger effect on apoCIII markers than the others (Additional file 3). We did not find an obvious dose-dependent effect in different doses of atorvastain treatment (Additional file 4). As an inflammation factor, HsCRP (3.25 ± 3.38 mg/L vs 2.22 ± 2.49 mg/L) was also significantly decreased after statin treatment \(( p < 0.01)\). In further analysis, the effect of statin treatment on apoCIII markers were minor in CHD patients with DM \(( p > 0.05)\), but the effect on plasma apoCIII (11.14 ± 3.72 mg/L vs 12.95 ± 5.75 mg/L) and HDL-apoCIII (25.19 ± 15.39 ug/mgHDL vs 30.84 ± 16.92 ug/mgHDL) were significant in CHD patients without DM (Additional file 5, \( p < 0.05)\).

| Variables Non-CHD \((n = 80)\) | CHD \((n = 120)\) | \( p \) |
|---------------------------------|-----------------|-----|
| Male (%)                        | 55.0            | 76.7| 0.002|
| Age (years)                     | 51.34 ± 8.35    | 55.52 ± 10.04 | 0.002|
| BMI (kg/m²)                     | 26.19 ± 3.23    | 26.31 ± 3.50  | 0.697|
| Hypertension (%)                | 47.5            | 58.3 | 0.191|
| Diabetes (%)                    | 11.3            | 12.2 | 0.247|
| TC (mmol/L)                     | 4.71 ± 0.80     | 4.49 ± 0.94  | 0.088|
| TG (mmol/L)                     | 1.62 ± 0.00     | 1.76 ± 0.84  | 0.079|
| HDL-c (mmol/L)                  | 1.24 ± 0.36     | 1.02 ± 0.23  | <0.001|
| LDL-c (mmol/L)                  | 3.03 ± 0.78     | 2.88 ± 0.82  | 0.199|
| ApoAI (mmol/L)                  | 1.48 ± 0.29     | 1.34 ± 0.24  | 0.001|
| ApoB (mmol/L)                   | 1.07 ± 0.22     | 1.16 ± 0.31  | 0.020|
| Glucose (mmol/L)                | 5.64 ± 1.36     | 5.43 ± 1.56  | 0.327|
| HsCRP (mg/L)                    | 1.75 ± 1.72     | 3.66 ± 3.58  | <0.001|
| ApoCIII (mg/L)                  | 12.68 ± 3.74    | 11.97 ± 4.94 | 0.275|
| HDL-apoCIII (ug/mgHDL)          | 21.00 ± 11.33   | 25.05 ± 12.98 | 0.024|
| Data are expressed as mean ± standard deviation or percent (%). CHD = coronary heart disease; BMI = body mass index; TC = total cholesterol; TG = triglyceride; HDL-c = high density lipoprotein cholesterol; LDL-c = low density lipoprotein cholesterol; Apo = apolipoprotein; HsCRP = high sensitivity C-reactive protein; HDL-apoCIII = apoCIII content in HDL.

Table 2 Odds ratios (OR) and 95 % confidence intervals (CI) of variables for predicting CHD
| Variables | Statin treatment \((n = 63)\) | \( p \) |
|-----------|-------------------------------|-----|
|           | Pre-treatment                | Post-treatment | |
| TC (mmol/L) | 4.45 ± 0.98                  | 3.85 ± 0.87     | <0.001|
| TG (mmol/L)  | 1.68 ± 0.77                  | 1.54 ± 0.76     | 0.138|
| HDL-c (mmol/L) | 1.05 ± 0.25                | 1.21 ± 0.54     | <0.001|
| LDL-c (mmol/L) | 2.84 ± 0.84                | 2.19 ± 0.69     | <0.001|
| ApoAI (mmol/L) | 1.37 ± 0.24                | 1.49 ± 0.30     | <0.001|
| ApoB (mmol/L)  | 1.16 ± 0.34                  | 0.89 ± 0.29     | <0.001|
| ApoCIII (mg/L) | 11.30 ± 4.10                | 12.93 ± 5.71     | 0.045|
| HDL-apoCIII (ug/mgHDL) | 24.26 ± 14.80 | 29.35 ± 16.46 | 0.003|

CHD = coronary heart disease; TC = total cholesterol; TG = triglyceride; HDL-c = high density lipoprotein cholesterol; LDL-c = low density lipoprotein cholesterol; Apo = apolipoprotein; HDL-apoCIII = apoCIII content in HDL.
HDL-apoCIII had significant correlations with plasma TG in non-CHD patients and CHD patients (Fig. 1a and b, \( p < 0.05 \)), but this correlation disappeared after statin treatment (Fig. 1c, \( p > 0.05 \)). However, plasma apoCIII had a moderate correlation with TG in non-CHD, CHD and statin treated CHD patients (\( r = 0.50, 0.59 \) and 0.58 respectively, \( p < 0.001 \)); and HDL-apoCIII significantly correlated to plasma apoCIII regardless of whether statin drugs were used or not (\( r = 0.35, 0.31 \) and 0.35 respectively, \( p < 0.05 \)). In this study, we did not find significant correlations between HDL-apoCIII or plasma apoCIII and HDL-c or LDL-c (\( p > 0.05 \)).

**Discussion**

In this study, we found that CHD patients had a significant higher level of HDL-apoCIII than non-CHD patients, and the association between HDL-apoCIII and CHD was still significant after adjusting for other variable factors. However, although conventional atherogenic lipid and inflammation factors were significantly decreased, there was a further elevation of HDL-apoCIII in CHD patients after statin treatment.

As an atherogenic factor, apoCIII exists in both HDL and apoB-lipoproteins, and transfers between them during the process of lipolysis [22–24]. Studies have found that apoCIII may participate in the initiation and progression of CHD through disturbing lipids metabolism, promoting the adhesion of monocyte to endothelial cell, and impairing the anti-apoptotic function of HDL [10–12, 15]. There were also some clinical studies found that HDL-apoCIII was significantly higher in CHD patients than in non-CHD patients, which can be used to predict the occurrence and progression of CHD, as well as the recurrent cardiovascular event [8, 16, 17]. In this study, in order to avoid potential effects of the concentration of HDL samples, we adjusted HDL-apoCIII values by the concentration of HDL after measuring apoCIII of HDL samples. And we also found a significantly higher HDL-apoCIII in CHD patients than non-CHD patients, and it still associated with CHD significantly after adjusting for other variable factors. To some extent, HDL-apoCIII was a better predictor of CHD than most conventional lipid markers.

This is the first time we quantitatively measured a significant elevation of HDL-apoCIII in CHD patients with adjustment of the effect of HDL sample, and established the association between HDL-apoCIII and CHD without the effect of lipid-lowering drugs. We also found an inverse association of HDL-c and HDL-apoCIII with CHD, a higher HDL-c predicts a lower risk of CHD, but a higher HDL-apoCIII predicts a higher risk of CHD, this finding was supported by the results of previous studies [4, 5, 17, 18]. Studies have found that HDL lost its anti-inflammatory and anti-atherogenic function in end-stage renal diseases or acute phase response [25–27]. Perhaps this condition also existed in CHD patients, and the elevated HDL-apoCIII may be partly responsible for the dysfunction of HDL in CHD patients, and the occurrence and progression of CHD. However, considered the
inhibitory effect of apoCIII on lipolysis [24], the elevated HDL-apoCIII may delay the further lipolysis of HDL in CHD patients also. So, the biological function of HDL-apoCIII in CHD patients may need further more study.

Lipid-lowering drugs, especially statins, are famous for their cardiovascular protective role by decreasing atherogenic, elevating antiatherogenic lipids and inhibiting inflammation response [19, 20, 28, 29]. An earlier study indicated that lipid-lowering drugs (colestipol hydrochloride and niacin) significantly decreased conventional lipids and delayed the progression of CHD, but they significantly increased HDL-apoCIII [18]. Another study also found although most CHD patients received statin treatment, they still had higher apoCIII contents in plasma and HDL, and the elevated apoCIII in HDL was responsible for the impaired antiapoptotic effect of HDL [15]. There was little studies reported that atorvastatin can decrease plasma apoCIII [30], but this result was still controversial [31]. In this study, we found a similar effect of statin treatment on atherogenic lipids and inflammation factor as previous studies [19, 20, 29, 32], however, not as expected, plasma apoCIII, especially HDL-apoCIII has a significant elevation at the same time. The result was partly consistent to previous studies [15, 18], and all the results favored the theory of apoCIII transfer, increased lipolysis of TRL leads to increased transfer of apoCIII to HDL. However, no matter the elevation of HDL-apoCIII was naturally or caused by statin treatment, an excessive elevated HDL-apoCIII may impair, and even counteract the antiatherogenic effect of HDL and/or the benefits of statin treatment. All the results might explain why further elevating HDL-c could not increase heart benefits [6, 7], and why there were still residual cardiovascular risks after statin treatment in CHD patients [33, 34].

We found a similar effect of statin treatment on lipid markers in CHD patients with DM or not. Perhaps because of the small case number or the interaction of antidiabetic drugs, we did not find a significant effect of statin treatment on apoCIII markers in patients with DM (n = 10). Our results were inconsistent with a previous study, which found a decrease of apoCIII in plasma and HDL in DM patients after atorvastatin treatment [35]. DM patients have higher risk of CHD than non-diabetic patients [36, 37], although statin treatment reduces the risk of CHD by decreasing lipids, it also leads to an increased risk of DM [38]. To date, there is little information about the differences of effects of statins on lipid markers among CHD patients, DM patients and CHD patients with DM, maybe the effect are different among them.

As reported previously [39], we also found a significant correlation between HDL-apoCIII and TG. Perhaps because of the effect of dyslipidemia and statin drugs, the correlation was weaker in CHD patients, and disappeared after statin treatment. However, the correlation between apoCIII and TG or HDL-apoCIII was not affected by statin drugs. As a part of the theory of apoCIII transfer, we did not find a significant correlation between HDL-apoCIII and HDL-c or LDL-c.

Limitations
An important limitation of our study was that there were no placebo controls because all the CHD patients received statin treatment. However, to some extent, the self-control method and the consistency of the results to previous studies favor the accuracy of the study. Although ultracentrifuge is a golden standard to isolate HDL, and we adjusted potential effect of HDL samples on the apoCIII results as far as possible, there may be some bias existing inevitably during the procedure.

Conclusions
Our study found that, HDL-apoCIII has a positive and significant association with CHD. Although statin treatment for CHD patients could decrease conventional atherogenic lipid markers significantly, HDL-apoCIII also has a significant elevation. The results may indicate a new aspect for studying CHD and evaluating the effect of statin treatment on the biological function of HDL in CHD patients.

Additional files

| Additional file 1: Baseline characteristics of all patients stratified by sex. (DOC 39 kb) |
| Additional file 2: Baseline characteristics of CHD patients with followed data or not. (DOC 37 kb) |
| Additional file 3: Effect of different types of statins on lipid variables in CHD patients. (DOC 36 kb) |
| Additional file 4: Effect of different doses of atorvastatin on lipid variables in CHD patients. (DOC 36 kb) |
| Additional file 5: Effect of statin treatment on lipid variables in CHD patients with DM or not. (DOC 37 kb) |

Abbreviations
CHD: Coronary heart disease; DM: Diabetes mellitus; TC: Total cholesterol; TG: Triglyceride; HDL-c: High density lipoprotein cholesterol; LDL-c: Low density lipoprotein cholesterol; Apo: Apolipoprotein; HsCRP: High sensitivity C-reactive protein; HDL-apoCIII: apoCIII content in HDL; TRL: Triglyceride-rich lipoproteins.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XX-W and LH took part in study design, data analysis and writing the manuscript. WD-X, HL and ZH recruited the patients, isolated high density protein cholesterol samples and assayed the data. LY-S initiated and designed the study. All authors read and approved the final version of this manuscript.
References

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

2. The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.

3. Steinberg D. Hypercholesterolemia and inflammation in atherosclerosis: Two sides of the same coin. Mol Nutr Food Res. 2005;49(11):995–8.

4. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorel PF, Catellier D, et al. Coronal heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The atherosclerosis Risk in Communities (ARIC) study. Circulation. 2001;104(10):1188–13.

5. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Njus ET, et al. Major risk factors for vascular disease. N Engl J Med. 2008;359(2):138–50.

6. Nissen SE, Tardif JC, Nicholls SJ, R Core Team, D ’Agostino RB, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304–14.

7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Apolipoprotein C-III and the metabolic syndrome. JAMA. 2009;302(18):1993–2000.

8. Nissen SE, Tardif JC, Nicholls SJ, R Core Team, D ’Agostino RB, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304–14.

9. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Apolipoprotein C-III and the metabolic syndrome. JAMA. 2009;302(18):1993–2000.

10. Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2002;105(1):40–10.

11. Vaia T. Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol. 2012;10(4):410–21.

12. Zheng C, Kho C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2002;105(1):40–10.

13. Kawakami A, Akawa M, Alcaide P, Luscasinska FW, Libby P, Sacks FM. Apolipoprotein C-III induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytes. Circulation. 2006;114(7):681–7.

14. Kawakami A, Akawa M, Libby P, Alcaide P, Luscasinska FW, Sacks FM. Apolipoprotein C-III in apolipoprotein B lipoproteins enhances the adhesion of human monocyte to endothelial cells. Circulation. 2006;113(5):691–700.

15. Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotein C-III and risk of the coronary heart disease. Circulation. 2011;124(19):2065–72.

16. Scheffer PG, Teerling JM, Delcroix C. Metabolism of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J Lipid Res. 1993;34(10):1793–803.

17. Chang PY, Lee CM, Hsu HC, Lin HJ, Chien KL, Chen CH, et al. Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan. Lipids Health Dis. 2012;11:162.

18. Blankenhorn DH, Aalaopovic P, Wickam E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 1990;81(2):470–6.

19. Law MR, Wald NJ, Rudnitska AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.

20. Jones PH, Davidson MH, Stein EA, Bays HE, McKinney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Ann Intern Med. 2003;139(2):152–60.

21. Yan LR, Wang DX, Liu H, Zhang XX, Zhao H, Hua L, et al. A pro-atherogenic HDL profile in coronary heart disease patients: an ITraq labeling-based proteomic approach. PLoS One. 2014;9(5):e98368.

22. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci. 2008;114(10):611–24.

23. Malmendier CL, Lontie JF, Grutman GA, Delcroix C. Metabolism of apolipoprotein C-III in normolipemic human subjects. Atherosclerosis. 1998;69(1):51–9.

24. Tornoczi L, Scheraldi CA, Li X, Ide H, Goldberg JJ, Le NA. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J Lipid Res. 1993;34(10):1793–803.

25. Speer T, Rohrer L, Blazka P, Snijders K, Kuschniker N, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38(4):754–68.

26. Tolle M, Huang T, Schuchardt M, Jankowski V, Pruner N, Jankowski J, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res. 2012;94(1):154–62.

27. Van Lenten BJ, Hama SY, de Bee FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cocultures. J Clin Invest. 1995;96(6):2758–67.

28. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear factor-kappaB in endothelial cells. J Cardiovasc Pharmacol. 2007;49(6):376–83.

29. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.

30. Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia effect of triglyceride reductions with atorvastatin. Metabolism. 2000;49(2):167–77.

31. Aalaopovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, et al. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose antiocoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis. 1999;146(2):369–79.

32. Zheng C, Aikawa E, Figueiredo J, Croce K, Sonoki H, et al. Statins suppress apolipoprotein C-III-induced vascular endothelial cell activation and monocyte adherence. Eur Heart J. 2013;34(8):615–24.

33. Singh IM, Shishehbor MH, Ansell BJ. High-density Lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298(7):796–88.

34. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Aki EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338:b92.

35. Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H. Atorvastatin and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis. 1999;146(2):369–79.

36. Stamler J, Vaccaro O, Neaton JD, Wentworth D, Diets, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–40.

37. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc. 2012;1(2):e000232. doi:10.1161/JAHA.111.002322.
38. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–71.

39. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, et al. Apolipoprotein c-III, a strong discriminator of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168(1):81–9.